Li, Y., Wong, M., Zhan, L., Corke, L., Brown, M.C., Cheng, S., Khan, K., Balatnaram, K., Chowdhury, M., Sabouhanian, A., Herman, J., Walia, P., Strom, E, Patel, D., García-Pardo, M., Schmid, S., Eng, L., Sacher, A.G., Leighl, N., and Bradbury, P.A.
• Non-small cell lung cancer (NSCLC) patients with single organ metastases (SOM) tends to have better overall survival than those with multiple organ metastases (MOM). • NSCLC patients with SOM exhibit distinct metastasis patterns and molecular profiles compared to those with MOM. • NSCLC SOM treatments vary by metastatic site. Studies would be beneficial to identify tailored treatment plans to optimize outcomes for this group. • Future studies should include SOM as a distinct category for NSCLC cases in survival analysis and consider it as a stratification factor in clinical trials. There is a paucity of information about the characteristics, treatment patterns, and outcomes of non-small cell lung cancer (NSCLC) patients with single organ metastasis (SOM). This retrospective cohort study includes all patients with a diagnosis of stage IV NSCLC diagnosed from 2014 to 2016 and treated at Princess Margaret Cancer Centre. We compared baseline characteristics and patterns of metastatic sites between patients with SOM versus multiple (M)OM. Additionally, we identified treatment modalities and outcomes for patients with SOM. Cox multivariable models (MVA) were utilized to evaluate differences in overall survival (OS) between the SOM and MOM cohorts. Of 893 pts analyzed, 457 (51 %) had SOM, while 436 (49 %) had MOM at initial diagnosis. Demographics were comparable between the two groups. Brain was the most common site of metastasis for SOM patients. When compared to the MOM group, the SOM group had lower percentages of liver and adrenal metastases. Amongst SOM patients, 54 % received single modality treatment, and 20 % did not receive any treatment for their SOM. In MVA, patients with liver (HR 2.4), bone (HR 1.8), and pleural (HR 1.7) metastasis as their SOM site had the worst outcomes, with median OS of 6.8 months, 12.1 months, and 13.0 months respectively. Patients with SOM had a significantly improved median OS compared to those with MOM (15.9 months vs. 10.6 months; HR 0.56, 95 % CI 0.47–0.66, p < 0.001). In NSCLC patients who presented with SOM, survival correlated with the initial organ involved and was better overall compared to patients with MOM. SOM NSCLC may benefit from specific management strategies and SOM patients could be considered as a specific subgroup for survival analyses in observational and non-randomized interventional studies. In clinical trials, SOM can be considered as a stratification factor in the future. [ABSTRACT FROM AUTHOR]